In the treatment of ovarian cancers, 40–70% of BRCA1/2 mutated patients failed to respond to PARP inhibitors.586 Platinum sensitivity is also reported as a prospective indicator for predicting the response to these inhibitors.587 Nevertheless, these two predictors still cannot completely cover the tumor types suitable for PARP inhibitor treatment. This evidence concerns the gene PARP1 and ovarian carcinoma.